Core Insights - Verastem, Inc. is a biopharmaceutical company focused on developing and commercializing medicines for cancer patients, attracting attention from momentum investors due to its recent performance and analyst projections [1] Price Targets and Performance - RBC Capital set a price target of $13 for Verastem, indicating a potential increase of 62.3% from the current stock price of $8.01 [2][6] - Zacks Investment Research assigned Verastem a Momentum Style Score of A, suggesting strong potential for continued positive performance, with a current trading price of $9.22 and a 1.9% gain over the past four weeks [3][6] - Wall Street analysts have a price target range for Verastem from $13 to $20, indicating potential increases of 41% to 116.9% [5][6] Stock Performance and Market Data - The stock price has recently decreased by 7.97% to $8.49, with a trading range today between $6.98 and $9.02, and a yearly range from a low of $2.95 to a high of $11.25 [4] - Verastem's market capitalization is approximately $522.2 million, with a trading volume of 4,762,954 shares on the NASDAQ exchange [4]